ArticleInternational cancer conference journal2025
Cardiomyopathy temporally associated with prior palbociclib treatment successfully treated with quadruple therapy for heart failure: a case report.
Article in International cancer conference journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor that has demonstrated in combination with fulvestrant longer progression-free survival in the setting of advanced breast cancer. Although palbociclib has a relatively favorable toxicity profile, several cardiovascular events have been described including cardiomyopathy. However, adequate management of cardiotoxicity in this setting remains unclear. A 55-year-old female patient with metastatic breast cancer was admitted due to heart failure after finishing chemotherapy with palbociclib. Transthoracic echocardiography (TTE) showed a left ventricular ejection fraction (LVEF) of 30% and severe mitral regurgitation (MR). Under the suspicion of cardiomyopathy temporally associated with prior palbociclib treatment, quadruple therapy with angiotensin receptor-neprilysin inhibitor (ARNI), betablockers, mineralocorticoid receptor antagonist (MRA), and sodium-glucose cotransporter 2 inhibitor (iSLGT2) was initiated. Three months after medical therapy, the patient recovered LVEF up to 56%, and there was not MR on control TTE. This case illustrates that quadruple therapy for heart failure may be a viable option to achieve complete LVEF recovery in a case of cardiomyopathy occurring after palbociclib exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.